drugset
drugset / Trial / NCT03527888

Study of Anlotinib in Patients With Primary Malignant Bone Tumors

NCT03527888 ↗

Phase 2 Unknown 40 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and efficacy of patients with recurrent and metastatic bone tumors.

Timeline

Start
2018-01-31
Primary completion
2019-12-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — Oral

Indications

bone cancer